P33 Methylation in Fecal DNA As a Molecular Screening Tool for Colorectal Cancer and Precancerous Lesions

Overview

Journal Oncol Lett

Specialty Oncology

Date 2014 Apr 26

PMID 24765192

Citations 3

Authors

Chun-Gang He

Qin-Yuan Huang

Li-Sheng Chen

Zhi-An Ling

Hong-Gen Wu

Hong-Qiang Deng

Affiliations

Soon will be listed here.

Abstract

The present study aimed to investigate the feasibility of detecting p33 inhibitor of growth 1b (p33) gene methylation in fecal DNA as a screening method for colorectal carcinoma (CRC) and precancerous lesions. The methylation of p33 was analyzed in fecal samples from 61 patients with CRCs, 27 patients with precancerous lesions (advanced adenoma) and 20 normal individuals by nested methylation-specific polymerase chain reaction (nMSP) and fecal occult blood test. Methylated p33 was detected in 73.77% of CRC patients and 62.96% of adenoma patients. By contrast, only 5% of normal individuals had methylated p33. These results indicated 73.77% sensitivity for detecting CRC, 62.96% sensitivity for detecting precancerous lesions and 95% specificity of the assay for detecting CRCs and precancerous lesions. The detection of p33 methylation status by incubation of DNA contained in agarose beads for bisulfite modification, followed by nMSP, is a promising non-invasive screening method for CRCs and precancerous lesions.

Citing Articles

and Methylation in Stool DNA for Early Detection of Colorectal Cancer.

Cao Y, Zhao G, Yuan M, Liu X, Ma Y, Cao Y Front Oncol. 2021; 10:621295.

PMID: 33585248 PMC: 7878552. DOI: 10.3389/fonc.2020.621295.

Fecal DNA methylation markers for detecting stages of colorectal cancer and its precursors: a systematic review.

Raut J, Guan Z, Schrotz-King P, Brenner H Clin Epigenetics. 2020; 12(1):122.

PMID: 32778176 PMC: 7418412. DOI: 10.1186/s13148-020-00904-7.

The importance of stool DNA methylation in colorectal cancer diagnosis: A meta-analysis.

Mojtabanezhad Shariatpanahi A, Yassi M, Nouraie M, Sahebkar A, Varshoee Tabrizi F, Kerachian M PLoS One. 2018; 13(7):e0200735.

PMID: 30024936 PMC: 6053185. DOI: 10.1371/journal.pone.0200735.

References

Shen D, Chan K, Khoo U, Ngan H, Xue W, Chiu P . Epigenetic and genetic alterations of p33ING1b in ovarian cancer. Carcinogenesis. 2005; 26(4):855-63. DOI: 10.1093/carcin/bgi011. View

Collins J, Lieberman D, Durbin T, Weiss D . Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med. 2005; 142(2):81-5. DOI: 10.7326/0003-4819-142-2-200501180-00006. View

Muller H, Oberwalder M, Fiegl H, Morandell M, Goebel G, Zitt M . Methylation changes in faecal DNA: a marker for colorectal cancer screening?. Lancet. 2004; 363(9417):1283-5. DOI: 10.1016/S0140-6736(04)16002-9. View

Pehlivan S, Artac M, Sever T, Bozcuk H, Kilincarslan C, Pehlivan M . Gene methylation of SFRP2, P16, DAPK1, HIC1, and MGMT and KRAS mutations in sporadic colorectal cancer. Cancer Genet Cytogenet. 2010; 201(2):128-32. DOI: 10.1016/j.cancergencyto.2010.05.019. View

Wang D, Tang D . Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol. 2008; 14(4):524-31. PMC: 2681142. DOI: 10.3748/wjg.14.524. View

Mandel J, Bond J, Church T, Snover D, Bradley G, SCHUMAN L . Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993; 328(19):1365-71. DOI: 10.1056/NEJM199305133281901. View

Lenhard K, Bommer G, Asutay S, Schauer R, Brabletz T, Goke B . Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol. 2005; 3(2):142-9. DOI: 10.1016/s1542-3565(04)00624-x. View

Gunduz M, Ouchida M, Fukushima K, Hanafusa H, Etani T, Nishioka S . Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. Cancer Res. 2000; 60(12):3143-6. View

Imperiale T, Ransohoff D, Itzkowitz S, Turnbull B, Ross M . Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004; 351(26):2704-14. DOI: 10.1056/NEJMoa033403. View

10.

Azuara D, Rodriguez-Moranta F, de Oca J, Soriano-Izquierdo A, Mora J, Guardiola J . Novel methylation panel for the early detection of colorectal tumors in stool DNA. Clin Colorectal Cancer. 2010; 9(3):168-76. DOI: 10.3816/CCC.2010.n.023. View

11.

Zhang Z, Sun D, Nguyen Van D, Tang A, Hu L, Huang G . Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int J Cancer. 2006; 120(1):32-8. DOI: 10.1002/ijc.22185. View

12.

Heresbach D, Manfredi S, Dhalluin P, Bretagne J, Branger B . Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol. 2006; 18(4):427-33. DOI: 10.1097/00042737-200604000-00018. View

13.

Rojas A, Meherem S, Kim Y, Washington M, Willis J, Markowitz S . The aberrant methylation of TSP1 suppresses TGF-beta1 activation in colorectal cancer. Int J Cancer. 2008; 123(1):14-21. PMC: 2777657. DOI: 10.1002/ijc.23608. View

14.

Herman J, Graff J, Myohanen S, Nelkin B, Baylin S . Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93(18):9821-6. PMC: 38513. DOI: 10.1073/pnas.93.18.9821. View

15.

Hellebrekers D, Lentjes M, van den Bosch S, Melotte V, Wouters K, Daenen K . GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res. 2009; 15(12):3990-7. DOI: 10.1158/1078-0432.CCR-09-0055. View

16.

Grunau C, Clark S, Rosenthal A . Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res. 2001; 29(13):E65-5. PMC: 55789. DOI: 10.1093/nar/29.13.e65. View

17.

Palmisano W, Divine K, Saccomanno G, Gilliland F, Baylin S, Herman J . Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000; 60(21):5954-8. View

18.

Mittag F, Kuester D, Vieth M, Peters B, Stolte B, Roessner A . DAPK promotor methylation is an early event in colorectal carcinogenesis. Cancer Lett. 2005; 240(1):69-75. DOI: 10.1016/j.canlet.2005.08.034. View

19.

Lee B, Lee E, Jung E, Chun H, Chang D, Song S . Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res. 2009; 15(19):6185-91. DOI: 10.1158/1078-0432.CCR-09-0111. View

20.

Liu W, Guan M, Su B, Li J, Ma W, Liu C . Rapid determination of AKAP12 promoter methylation levels in peripheral blood using methylation-sensitive high resolution melting (MS-HRM) analysis: application in colorectal cancer. Clin Chim Acta. 2010; 411(13-14):940-6. DOI: 10.1016/j.cca.2010.03.003. View